Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
04/30/2025
04/30/2024
04/30/2023
04/30/2022
04/30/2021
Ingresos
58
56
50
53
49
41
Crecimiento de los Ingresos (YoY)
9%
12%
-6%
8%
20%
28%
Costo de los ingresos
29
28
29
29
23
21
Utilidad bruta
29
28
20
24
25
19
Venta, General y Administración
18
16
18
17
15
12
Investigación y Desarrollo
8
6
9
11
9
7
Gastos de Operación
26
23
27
28
24
19
Otras Ingresos (Gastos) No Operativos
0
0
--
0
0
0
Ingreso antes de impuestos
2
4
-7
-5
0
0
Gasto por Impuesto a la Renta
0
0
0
0
0
0
Ingreso Neto
2
4
-7
-5
0
0
Crecimiento de la Utilidad Neta
--
-157%
40%
--
--
-100%
Acciones en Circulación (Diluidas)
14.45
14.26
13.54
13.54
14.16
14.57
Cambio de Acciones (YoY)
3%
5%
0%
-4%
-3%
23%
EPS (Diluido)
0.16
0.32
-0.53
-0.39
0.04
0.02
Crecimiento de EPS
-442%
-161%
38%
-1,075%
100%
-112%
Flujo de efectivo libre
5
6
-6
1
4
-4
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
50%
50%
40%
45.28%
51.02%
46.34%
Margen de operación
3.44%
7.14%
-12%
-7.54%
0%
0%
Margen de beneficio
3.44%
7.14%
-14%
-9.43%
0%
0%
Margen de flujo de caja libre
8.62%
10.71%
-12%
1.88%
8.16%
-9.75%
EBITDA
3
5
-5
-2
1
1
Margen de EBITDA
5.17%
8.92%
-10%
-3.77%
2.04%
2.43%
D&A para EBITDA
1
1
1
2
1
1
EBIT
2
4
-6
-4
0
0
Margen de EBIT
3.44%
7.14%
-12%
-7.54%
0%
0%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
0%
0%
Estadísticas clave
Cierre Anterior
$5.95
Precio de apertura
$5.99
Rango del día
$5.98 - $6.25
Rango de 52 semanas
$5.59 - $11.82
Volumen
1.8K
Volumen promedio
12.2K
EPS (TTM)
0.17
Rendimiento de dividendos
--
Cap. de mercado
$83.8M
¿Qué es CSBR?
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.